We describe a nonsense mutation in the regulatory domain of erythroid ankyrin associated with autosomal dominant hereditary spherocytosis with a selective deficiency of the ankyrin isoform 2.1 (55% of normal), a deficiency of spectrin (58% of normal) proportional to the decrease in ankyrin 2
Introduction
Erythroid ankyrin is a major red cell membrane protein that links the red cell membrane skeleton to the plasma membrane by interactions with spectrin, the major protein of the membrane skeleton, and band 3 protein, the major transmembrane protein of the red cell membrane ( 1-3 ). Ankyrin contains three distinct regions which differ in their function. These regions include the NH2 terminal domain which contains 24 homologous repeats and which is involved in the binding of band 3 protein, the central spectrin-binding domain, and the COOH-terminal regulatory domain (4, 5) (Fig. 1 A) . The regulatory domain of ankyrin is subject to extensive altemative splicing (4) (5) (6) (7) (8) . As a result, separation of membrane proteins in SDS-PAGE reveals a ladder of bands reacting with ankyrin antibodies. These bands include band 2.1, the full-size erythroid ankyrin, and additional bands designated as bands 2.2 to 2.6 (1, 9) .
Proteins 2.1 and 2.2 represent the two major ankyrin isoforms produced by altemative splicing (Fig. 1 B) . They differ in that the major portion of exon 38 (8) is deleted from the ankyrin 2.2 mRNA, due to a usage of an intraexon splice site (4, 5) (Fig. 1 C) . This altemative splicing produces a major difference in the function of these two ankyrin isoforms: protein 2.2 is an activated form of ankyrin in that it has threefold higher affinity for spectrin and binds to twice the number of high affinity band 3 sites (10). The 2.2 isoform is the predominant isoform of developing erythroblasts while protein 2.1 is the major ankyrin isoform of mature erythrocytes (6) .
Several studies have suggested that ankyrin mutations represent the underlying molecular defect in a subset of patients with hereditary spherocytosis (HS).' This common hereditary hemolytic disorder is heterogeneous in terms of inheritance, severity of hemolysis, and the underlying molecular defects which involve a spectrin, 3 spectrin, ankyrin, and the band 3 protein (for review see reference 11) . The data implicating ankyrin as the underlying molecular defect involve a report of a deletion of ankyrin gene on chromosome 8 (12) , restriction fragment length polymorphism study of a large family demonstrating a linkage of autosomal dominant HS to the ankyrin gene (13) , the coinheritance of an abnormally migrating ankyrin designated as ankyrinPRAGUE with the HS phenotype (14) , and a severe defect of ankyrin mRNA expression and ankyrin biosynthesis (15) . Recently, several ankyrin mutations have been reported in a preliminary form, which involves one nonsense mutation, and small insertions or deletions leading to a frameshift and premature chain termination (16) .
In this report, we describe a unique mutation in the regulatory domain of ankyrin in a kindred with autosomal dominant HS and a marked and selective deficiency of the content of ankyrin isoform 2.1 and a normal content of the second main ankyrin isoform 2.2. This deficiency of the 2.1 ankyrin isoform is accompanied by a proportional deficiency of spectrin. We find that the underlying genetic defect involves a nonsense mutation 1669Glu-*Ter (GAA-+TAA) in one allele of the ankyrin gene.
As a result, altemative splicing in the regulatory domain of ankyrin leads to a retention of codon 1669 in ankyrin 2.1 mRNA while it removes an exon containing this mutation from ankyrin 2.2 mRNA. The mutation could be detected in the genomic DNA, but it is nondetectable in the reticulocyte RNA, suggesting that the underlying cause of the selective ankyrin 2.1 deficiency involves instability of ankyrin 2.1 mRNA which con- Osmotic fragility is given as an interval between minimum osmotic resistance (normal range 0.48-0.44) and complete hemolysis (normal 0.34-0.30). 11 After development of cholelithiasis, total bilirubin levels increased to 7.6-9.1 mg/dl. § n.d., not determined. electrophoresed proteins were transferred to nitrocellulose, immunoreacted with the primary antibody and peroxidase-coupled secondary antibody, and the blot was developed using hydrogen peroxide and achloronaphthol.
Quantitation of band 3 copies by cytofluorometry. Band 3 protein was quantitated in individual red cells by cytofluorometry of eosin-5-maleimide (E5M)-labeled erythrocytes, essentially as described (23, 24) . Briefly, blood was washed three times with phosphate-buffered saline (PBS), and the buffy coat was carefully removed. 40 1l of packed red cells was resuspended in 1.76 ml of PBS with 0.5% bovine serum albumin (BSA) and 200 ,1 of a 1 mg/ml stock solution of E5M (Molecular Probes, Inc., Eugene, OR) was added. The suspension was incubated for 1 h in the dark at room temperature on a tube rocker, washed three times with PBS, and resuspended in PBS with 0.5% BSA. Erythrocytes were analyzed using a flow cytometer (PROFILE II; Coulter Corp., Hialeah, FL). Fluorescence at 525 nm and low angle and right angle scatter were measured for 20,000 cells in each sample, a histogram of fluorescence intensity was plotted, and the mean fluorescence intensity and the standard deviation were calculated.
Preparation of reticulocyte RNA and PCR amplification of ankyrin cDNA. Total reticulocyte RNA was isolated by ammonium chloride lysis (25) and reverse transcribed using random hexamers. A segment of cDNA coding for the regulatory domain of ankyrin was PCR amplified using a PCR reagents kit (GeneAmp; Perkin Elmer-Cetus, Norwalk, CT) and primers P401 (5 '-ACATCACCATGCCCCCCTGCGCTA-3'; nt 4163-4186) and P400 (5'-GCACCGCTGCGGTGGCCCTCA-3'; nt 5793-5773) ( Fig. 1 B) , 35 (4, 5) and can be readily PCR amplified from genomic DNA using the known cDNA sequence, it was necessary to determine the sequence of the donor splice site, i.e., sequence the 3' boundary of intron 37. For that, genomic DNA was isolated from a healthy individual and digested with restriction enzymes TaqI and DpnII. Plasmid pGEM4Z (Promega Corp., Madison, WI) was digested with AccI and BamHI, and cohesive ends of DNA and plasmid were ligated. The unknown sequence of intron 37 adjacent to exon 38 was PCR amplified from this ligation mixture using PCR primer A2 (5'-TTCCAGAGAGCCCAACTCGG-3', nt 4941-4922) within exon 38 (Fig. 1 C) and pGEM4Z primer T7 (5'-TAATACGACTCACTA-TAGGG-3'), 40 cycles, 1 min 94°C, 1 min 40°C, 2 min 72°C, and the product of the first amplification was reamplified with primer T7 and a nested primer A8 (5 '-CACGTAGCGGAGAGGAAAGTGC-3', nt 4693-4672) in exon 38 (Fig. 1 C) , 40 cycles, 1 min 94°C, 1 min 55°C, 2 min 72°C. The obtained PCR product of 520 bp was cloned into plasmid pCR II using the TA cloning kit (Invitrogen, San Diego, CA) and sequenced using Sequenase version 2.0 DNA sequencing kit (United States Biochemicals Corp., Cleveland, OH).
Sequencing of patient genomic DNA. After sequencing of the 3' end of intron 37, most of the patient ankyrin exon 38 and the adjacent acceptor splice site of intron 37 was PCR amplified (35 cycles, 1 min 94°C, I min 55°C) using primer A16 (5'-CTAGATGCATGCTCG-AGCGG-3'; nt -63 to -44) and primer AIO (5 '-CTCCTCTCCGTC-ACCTGACTC-3'; nt 5171-5151) (Fig. 1 C) , phosphorylated at the 5'-end (3 ag 
Results
Ankyrin"KOVNJK red cells are markedly deficient in ankyrin isoform 2.1 and spectrin while having a normal amount of the ankyrin 2.2 isoform. Red cell membranes from both affected individuals were prepared and analyzed by SDS-PAGE in 3.5-17% exponential gradient gels. Densitometry of Coomassie blue stained gel followed by calculation of spectrin to band 3, ankyrin 2.1 to band 3, and ankyrin 2.2 to band 3 ratios revealed a 15% decrease in spectrin to band 3 ratio, an 18% decrease in ankyrin 2.1 to band 3 ratio, and a 52% increase in ankyrin 2.2 to band 3 ratio (Fig. 2 A and Table II ). In accordance with the above results of densitometric determination, immunoblotting with antiankyrin antibodies revealed a relative increase in staining of the 2.2 band (Fig. 2 B) . In addition to the densitometric analysis, we used flow cytometry of E5M-labeled cells to quantitate band 3 in single cells. ESM binds specifically to band 3
Hereditary Spherocytosis Due to a Nonsense Mutation in Ankyrin Gene 943 message. To sequence this whole region, we first sequenced the unknown 3 '-end of the preceding intron 37. PCR amplification with primers T7 and A8 of control genomic DNA, digested with TaqI and DpnII and ligated into the pGEM4Z plasmid digested with AccI and BamHI, yielded a product of 517 bp that was cloned and sequenced. Its sequence comprised 69 bp of exon 38, the rest being derived from intron 37. We sequenced 70 bases at the 3' end of intron 37, prepared an intronic primer A16 (5 '-CTAGATGCATGCTCGAGCGG-3'; nt -63 to -44) ( Fig. 1 C) , and PCR amplified a 613-bp segment of patient genomic DNA comprising most of exon 38 and the adjacent part of intron 37 using primer A16 and primer A0 phosphorylated at the 5 '-end. Single-stranded template was prepared and directly sequenced. Sequencing revealed a transversion G-+T in codon 1669 that replaces GAA (glutamic acid) by TAA (termination codon) (Fig. 4) . This mutation changes the normal sequence of codons 1668 and 1669 (4) from AATGAA to AATTAA and thus creates a MseI restriction site TTAA. Digestion with the MseI restriction endonuclease of a 296-bp PCR product, obtained by PCR amplification of genomic DNA using primers Al and AIO, was therefore used to evaluate the presence of the mutation in the studied kindred. Portion of the PCR product, corresponding presumably to one ankyrin allele, was cleaved into two bands of 213 and __ Figure 3 . PCR amplifi-12300-2 cation of cDNA corresponding to the regula-61. 5- 83 bp in all three affected family members (data for two patients are shown in Fig. 5 , lanes 4 and 6), while the PCR-amplified control genomic DNA was left intact (Fig. 5, lanes 8 and 10) . This result confirmed the presence of the G-iT transversion in codon 1669 in all three affected family members. The mutant ankyrin 2.1 mRNA is not detected in ankyrinRAfKWIwK reticulocytes. The two most likely mechanisms leading to ankyrin 2.1 deficiency are (a) synthesis of a dysfunctional 182-kD peptide that is not stably incorporated into the membrane skeleton or (b) decrease in the mutant 2.1 mRNA content due to its instability. We did not detect any abnormally migrating protein in the cell membranes (Fig. 1) or in whole red cell lysates (not shown). Using primers Al and AIO, we PCR amplified a 296-bp segment of the 2.1 cDNA that should contain the 1669Glu-*Ter mutation. We directly sequenced the PCR product and detected only the normal ankyrin cDNA sequence (Fig. 4) . Similarly, using MseI restriction digestion, we detected only the normal allele in all three affected members of the studied kindred (results shown for two patients in Fig. 5 , lanes 3 and 5). We conclude that the amount of the ankyrin 2.1 mRNA that would contain the nonsense mutation is decreased in the reticulocytes below the levels detectable either by direct sequencing or by restriction digestion of the PCR-amplified cDNA.
Discussion
We analyzed ankyrin genomic DNA in three patients from a kindred with autosomal dominant HS and detected in all three of them a nonsense mutation 1669Glu-Ter in allele of the ankyrin gene. We designated the mutant ankyrin allele, based on the city of origin, as ankyrin'RAKOVNIK. The region of cDNA containing the mutation is spliced out from the mRNA encoding the ankyrin 2.2 isoform. Consequently, normal ankyrin 2.2 mRNA should be produced from both alleles, while both mutant and normal 2.1 mRNAs should be present. We detected only the normal ankyrin 2.1 mRNA in reticulocytes from the affected individuals. We found normal levels (105%) of protein 2.2 and a selective decrease (55% or normal) of protein 2.1.
In agreement with our inability to detect the mRNA containing the 1669Glu-*Ter substitution, we likewise were unable to detect the presence of a truncated ankyrin protein (predicted size 182 kD, as opposed to 206 kD for the normal ankyrin 2.1 isoform). We therefore conclude that the most likely mechanism of selective ankyrin 2.1 deficiency involves either a major decrease or a complete absence of the mutant 2.1 mRNA. We suggest that this decrease in the mutant mRNA is caused by the instability of this message and leads to a decreased synthesis of the 2.1 protein, while synthesis of the protein 2.2 remains normal. It has been well documented that nonsense mutations in messenger RNAs, with the exception of the 3 '-ends of the coding regions, cause a reduction in steady state mRNA levels by promoting rapid degradation of mutant mRNA molecules (for review see reference 28).
Another mechanism that could possibly account for decreased production of the protein 2.1 involves an increased usage of the altered intraexon splice site: the G-+T transversion is 19 nt upstream from the normal intraexon splice site which deletes most of exon 38 from the 2.1 mRNA and thus leads to the production of ankyrin 2.2 message (Fig. 6) (4, 5) . The substitution elongates the obligatory pyrimidine tract in the intraexon acceptor splice site from 10 to 11 (1, 3, 29, 30) , and its deficiency could therefore affect the normal structure and function of these tissues. As was shown by us (6, 7) and others ( 8, 31 ) , the main ankyrin isoform in the brain and the erythroid progenitors is protein 2.2. Protein 2.1 is the predominant ankyrin isoform of mature red cells. We therefore expect that the mutation described here, which involves only the 2.1 isoform, affects selectively the membrane of mature erythrocytes and does not have a major effect on maturing erythroid cells or brain cells expressing erythroid ankyrin. The expression of the 2.1 and 2.2 ankyrin isoforms in the muscle, endothelial cells, and macrophages has not been studied. However, the absence in the carriers of the mutation of symptoms that could be related to the expression of ankyrin in the other above mentioned tissues supports our conclusion that the predominantly affected cells are the mature erythrocytes.
It has been shown that ankyrin deficiency is in most cases associated with spectrin deficiency (32, 33) and that a decreased synthesis of ankyrin leads to a decreased assembly of spectrin on the plasma membrane (15) . The results presented here further demonstrate that a primary deficiency of ankyrin 2.1 leads to a secondary deficiency of spectrin which is of a similar magnitude as the ankyrin deficiency.
In conclusion, we report a nonsense mutation 1669Glu-+Ter in the regulatory domain of ankyrin associated with a moderately severe autosomal dominant HS. We suggest that a decreased stability of the mutant ankyrin 2.1 message leads to a primary deficiency of ankyrin 2.1, which in turn causes a secondary deficiency of spectrin.
